Spondyloarthritis & psoriatic arthritis
Association of the clinical components in the distal interphalangeal joint synovio-entheseal complex and subsequent response to ixekizumab or adalimumab in psoriatic arthritis
An erratum to this article was published (Rheumatology (Oxford), 1 Nov 2024 ↗)
Authors' conclusion
In this study cohort, patients with DIP joint involvement almost always had adjacent nail psoriasis. Greater resolution of DIP joint tenderness, swelling and adjacent nail psoriasis was achieved at all time points over 52 weeks through targeting IL-17A with IXE than TNF-α with ADA, which is noteworthy given prior comparable musculoskeletal outcomes for both drug classes.
Study context
- Population
- Patients with PsA with simultaneous distal interphalangeal (DIP) joint involvement (tenderness and/or swelling) and adjacent nail psoriasis in ≥1 digit at baseline, SPIRIT-H2H trial1,309 finger units
- Participants
- 354 patients
- Comparison
- Ixekizumab vs adalimumab
- Primary endpoint
- Complete resolution of affected finger units (DIP joint tenderness/swelling and adjacent nail psoriasis)
- Follow-up
- Week 52
Methodological detailspost hoc analysis, finger-unit level analysis
- Post hoc analysis
- Finger-unit level analysis
Primary result
As reported in the abstract
Affected finger units achieving complete resolution
P = 0.0055
Further findings
Affected finger units achieving complete resolution · week 12
P < 0.0001
Events
| Outcome | IXE | ADA |
|---|---|---|
| Affected finger units at baseline | 639 | 670 |
Original publication
Association of the clinical components in the distal interphalangeal joint synovio-entheseal complex and subsequent response to ixekizumab or adalimumab in psoriatic arthritis. Rheumatology (Oxford). Published 10 February 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →